原创 廖博士 廖博士国际新药快讯 今天
Moderna Announces First Participant Dosed Against Novel Coronavirus
Moderna公司宣布第一位受试者接受新冠疫苗注射
March 16, 2020
Moderna, Inc., today announced that the first participant has been dosed in the Phase 1 study of the Company’s mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2).
2020年3月16日
Moderna公司今天宣布，该公司针对新型冠状病毒（SARS-CoV-2）的mRNA疫苗（mRNA-1273）的I期临床研究的第一名参与者注射了该疫苗。
mRNA-1273 is Moderna’s 10th infectious disease vaccine to begin a clinical trial
mRNA-2173是Moderna公司第10个开始临床试验的传染病疫苗
mRNA-1273 is an mRNA vaccine against SARS-CoV-2 encoding for Spike (S) protein, which was selected by Moderna in collaboration with investigators from the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), a part of NIH. Manufacture of the first clinical batch was funded by the Coalition for Epidemic Preparedness Innovations (CEPI).
mRNA-1273是一种抗SARS-CoV-2的信使核糖核酸疫苗，编码S蛋白，由Moderna公司与NIH下属的国家过敏和传染病研究所（NIAID）疫苗研究中心（VRC）的研究人员合作设计。第一批临床试验的生产资金由防疫创新联盟（CEPI）资助。
A total of 45 healthy adults will be enrolled in the study. Participants will be followed through 12 months after the second vaccination.
共有45名健康成年人将被纳入这项研究。参与者将在第二次接种疫苗后的12个月内接受随访。
On January 11, 2020, the Chinese authorities shared the genetic sequence of the novel coronavirus. On January 13, 2020 the VRC and Moderna’s infectious disease research team finalized the sequence for the SARS-CoV-2 vaccine. The first clinical batch was completed on February 7, 2020 and underwent analytical testing; it was shipped on February 24, 2020 from Moderna and delivered to NIH from the Company’s manufacturing facility in 42 days from sequence selection.
2020年1月11日，中国官方公布了这种新型冠状病毒的基因序列。2020年1月13日，VRC和Moderna的传染病研究小组最终确定了SARS-CoV-2疫苗的序列。第一批临床试验疫苗于2020年2月7日完成生产，并进行了分析测试；于2020年2月24日从Moderna发货交付给NIH。从疫苗序列选择到从公司的工厂发货一共42天！
閱讀更多 醫界君 的文章
